Real-world pharmacotherapy with novel antipsychotics

Journal of Practical Psychiatry and Behavioral Health

Volumn 5, Issue 1, 1999, Pages 37-43

  Fichtner, Christopher G ^a,b   Luchins, Daniel J ^a,c   Malan, Randy D ^a   Hanrahan, Patricia ^a,c  

^a Illinois Department of Human Services   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Atypical antipsychotics; Clozapine; Cost effectiveness analyses; Medical effectiveness studies; Pharmacoeconomics; Riseridone

Indexed keywords

EID: 0006138011     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-199901000-00005     Document Type: Article

References (32)

1. Meltzer HY. New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 1993;16:365-85.
2. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
3. Keck PE, McElroy SL. The new antipsychotics and their therapeutic potential. Psychiatric Annals 1997;27:320-31.
4. Bachrach LL. Continuity of care and approaches to case management for long-term mentally ill patients. Hosp Comm Psychiatry 1993;44:465-8.
5. Hu T-W, Jerrell JM. Estimating the cost impact of three case management programmes for treating people with severe mental illness. Br J Psychiatry 1998;173(suppl 36):26-32.
6. Olfson M, Mechanic D, Boyer CA, Hanseil S. Linking inpatients with schizophrenia to outpatient care. Psychiatr Serv 1998;49:911-7.
7. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
8. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. Am J Psychiatry 1998;155:499-504.
9. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-10.
10. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
11. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: Treatment of schizophrenia, 1999. J Clin Psychiatry, in press.
12. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995;31:57-65.
13. Maynard A, Bloor K. Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals. Br J Psychiatry 1998;173(suppl 36):12-8.
14. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57(suppl 9):66-76.
15. Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997;22:256-66.
16. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997;58(suppl 10):50-4.
17. Fichtner CG, Hanrahan P, Luchins DJ. Pharmacoeconomic studies of atypical antipsychotics: Review and perspective. Psychiatric Annals 1998;28:381-96.
18. Lebowitz BD, Rudorfer MV. Treatment research at the millennium: From efficacy to effectiveness. J Clin Psychopharmacol 1998;18:1.
19. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacol Bull 1996;32:683-97.
20. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-15.
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
22. Mahmoud RA. Risperidone outcomes study of effectiveness: the RIS-USA-56 trial. Presented at the RIS-USA-56 investigators' meeting, Rancho Mirage, California, January 23-24, 1998.
23. Malan RD, Luchins DJ, Fichtner CG, Hanrahan P, Klass D. Discontinuity of outpatient antipsychotic pharmacotherapy: Risperidone maintenance after hospitalization. Manuscript in review.
24. Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press; 1991.
25. Cramer JA. Partial medication compliance: The enigma in poor medical outcomes. American Journal of Managed Care 1995;1:45-52.
26. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
27. Macharia S, Leon G, Rowe B, et al. An overview of interventions to improve compliance with appointment keeping for medical services. JAMA 1992;267:1813-7.
28. Himmel W, Tabache M, Kochen MM. What happens to long-term medication when general practice patients are referred to hospital? Eur J Clin Pharmacol 1996;50:253-7.
29. Cochrane RA, Mandal AR, Ledger-Scott M, Walker R. Changes in drug treatment after discharge from hospital in geriatric patients. BMJ 1992;305:694-6.
30. Corrigan PW, Liberman RP, Engel JD. From non-compliance to collaboration in the treatment of schizophrenia. Hosp Com Psychiatry 1990;41:1203-11.
31. Smoller JW, McLean RYS, Otto MW, Pollack MH. How do clinicians respond to patients who miss appointments? J Clin Psychiatry 1998;59:330-8.
32. Luchins DJ, Klass D, Hanrahan P, Malan R, Harris J. Alteration in the recommended dosing schedule for risperidone. Am J Psychiatry 1998;155:365-6.